MedCityNews: Cancer & immunology biotech Odyssey embarks with $218M, Gary Glick at helm

Frank Vinluan

At the start of 2021, serial biotech entrepreneur Gary Glick revealed a mega-round of financing for his new precision oncology startup. Now he’s back at it again, bringing along some familiar investors who have joined forces to raise even more money—$218 million—for yet another startup he founded, Odyssey Therapeutics. That biotech is setting out with programs already in development in cancer and immunology.

Read more